CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT ID: NCT04322955

Last Updated: 2025-04-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-22
• Study Completion Date: 2028-02-29

Brief Summary

The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.

Detailed Description

People with metastatic kidney cancer are usually treated with medications to slow the growth of the cancer. In addition, people who still have the kidney where the cancer started may have the kidney removed during the course of treatment. This surgery is done in order to decrease the amount of tumor in the body. This surgery is referred to as a cytoreductive nephrectomy. In the current study, nivolumab, an immune checkpoint inhibitor, is being administered in combination with cabozantinib, a targeted therapy. The combination of nivolumab and cabozantinib is FDA approved for the treatment of metastatic kidney cancer. In this study, treatment consists of cabozantinib and nivolumab plus a cytoreductive nephrectomy. Eligible subjects, who have not received prior therapy for metastatic clear cell renal cell carcinoma, are treated with cabozantinib and nivolumab for approximately 3 months prior to undergoing cytoreductive nephrectomy. After nephrectomy, patients who are benefiting from treatment may resume cabozantinib and nivolumab. This study will help investigators to understand the immune effects of cabozantinib and nivoluamb in the kidney tumor and will provide information on the potential clinical benefit associated with cytoreductive nephrectomy in combination with cabozanitnib and nivolumab.

Conditions

Kidney Cancer; Renal Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment with cabozantinib and nivolumab with nephrectomy

All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. Initially patients enrolled on the study will be assigned to cohort 1.

Patients who are assigned to cohort 1 will be treated with cabozantinib until 21 days prior to surgery. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval ("evaluable patients") if they

1. complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND

2. have surgical resection of the primary tumor.

In cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy.

Group Type: EXPERIMENTAL

Cabozantinib

Intervention Type: DRUG

2 x 20 mg capsules taken orally daily

Nivolumab

Intervention Type: DRUG

480mg IV on first day of each 28-day cycle

Cytoreductive nephrectomy

Intervention Type: PROCEDURE

Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.

Interventions

Cabozantinib

2 x 20 mg capsules taken orally daily

Intervention Type: DRUG

Nivolumab

480mg IV on first day of each 28-day cycle

Intervention Type: DRUG

Cytoreductive nephrectomy

Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.

Intervention Type: PROCEDURE

Other Intervention Names

XL184; BMS-936558

Eligibility Criteria

Inclusion Criteria

1. Written informed consent and HIPAA authorization for release of personal health information.

2. Age ≥ 18years at the time of consent.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days prior to registration.

4. Radiographically consistent with metastatic renal cell carcinoma (with subsequent pathologic confirmation of renal cell carcinoma with a clear cell component) OR histological/ cytological evidence of metastatic renal cell carcinoma with a clear cell component

5. Measurable tumor in the kidney according to RECIST 1.1

6. No prior therapy for metastatic renal cell carcinoma

7. Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.

8. Females of childbearing potential must have a negative serum pregnancy test during screening, within 14 days of Cycle 1 Day 1. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months

9. Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.

10. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion Criteria

1. Patients who had previously undergone nephrectomy for renal cancer are excluded

2. Uncontrolled bleeding, hypertension, or cardiovascular disease.

3. Prior treatment with any therapy on the PD-1/PD-L1 axis or anti- CTLA-4 inhibitors

4. The subject has active brain metastases or epidural disease

5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment.

6. The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test ≥1.3 x the laboratory upper limit of normal (ULN)

7. The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, thrombin or Factor Xa inhibitors. Aspirin (up to 325 mg/day), low-dose warfarin (≤1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permitted

8. Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment

9. Hemoptysis of ≥0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment

10. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.

11. The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib

12. Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment

13. Patients are excluded if they have a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study start

14. Cardiovascular disorders including:

• Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening
• Concurrent uncontrolled hypertension defined as sustained BP > 150 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 14 days of the first dose of study treatment.
• The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 28 days before registration.

15. Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment

16. Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment

17. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (e.g., simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.

18. History of organ transplant

19. Concurrent uncompensated hypothyroidism

20. Unable to swallow tablets

21. Active infection requiring systemic therapy

22. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).

23. Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least 2 years.

24. Active central nervous system (CNS) metastases

25. Treatment with any investigational drug within 28 days prior to registration.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Exelixis

INDUSTRY

Sponsor Role: collaborator

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Mark Stein

OTHER

Sponsor Role: lead

Responsible Party

Mark Stein

Associate Professor of Medicine Division of Hematology/Oncology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Mark N Stein, MD

Role: PRINCIPAL_INVESTIGATOR

Associate Professor of Medicine Division of Hematology/Oncology

Locations

The Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status: RECRUITING

Columbia University Irving Medical Center

New York, New York, United States

Site Status: RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status: RECRUITING

Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Research Nurse Navigator

Role: CONTACT

cancerclinicaltrials@cumc.columbia.edu

212-342-5162

Facility Contacts

Biren Saraiya, MD

Role: primary

732-235-2465

Research Nurse Navigator

Role: primary

cancerclinicaltrials@cumc.columbia.edu

212-342-5162

Moshe Ornstein, MD,MA

Role: primary

ornstem@ccf.org

917-587-3359

Eric Singer, MD, MS

Role: primary

eric.singer@osumc.edu

Other Identifiers

AAAS6927

Identifier Type: -

Identifier Source: org_study_id